Silo pharma advances intellectual property portfolio with provisional patent filing for ptsd treatment

Sarasota, fl, jan. 22, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the u.s. patent and trademark office (uspto). this application, focused on its lead asset spc-15, highlights silo's commitment to advancing treatments for stress-induced psychiatric disorders, including post-traumatic stress disorder (ptsd).
SILO Ratings Summary
SILO Quant Ranking